Get the Stockscreener App
144.41
0.29%
-0.42
Illumina Inc stock is traded at $144.41, with a volume of 899.39K.
It is down -0.29% in the last 24 hours and up +10.66% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$144.83
Open:
$144.69
24h Volume:
899.39K
Relative Volume:
0.55
Market Cap:
$21.85B
Revenue:
$4.39B
Net Income/Loss:
$853.00M
P/E Ratio:
26.21
EPS:
5.5097
Net Cash Flow:
$556.00M
1W Performance:
+1.31%
1M Performance:
+10.66%
6M Performance:
+16.60%
1Y Performance:
+79.30%
1-Day Range:
$143.17
$146.49
1-Week Range:
$138.64
$146.61
52-Week Range:
$78.55
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
144.41 | 21.91B | 4.39B | 853.00M | 556.00M | 5.5097 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina (ILMN) director Caroline Dorsa receives 2,072 RSUs and 1,512-share tax withholding update - Stock Titan
Illumina (ILMN) awards 2,072 restricted stock units to director - Stock Titan
Illumina (ILMN) director Scott B. Ullem receives 2,072-share RSU award - Stock Titan
Illumina (ILMN) director Philip Schiller receives 2,072-share restricted stock grant - Stock Titan
Illumina (ILMN) director Anna Richo granted 2,072 restricted stock units as equity pay - Stock Titan
Illumina (ILMN) director Keith Meister granted 2,072 RSUs and updates holdings - Stock Titan
Illumina (ILMN) director Scott Gottlieb receives 2,072-share RSU grant - Stock Titan
Illumina (ILMN) director David P. King submits initial Form 3 - Stock Titan
Illumina’s SWOT analysis: stock faces visibility concerns despite growth By Investing.com - Investing.com Canada
Understanding Momentum Shifts in (ILMN) - Stock Traders Daily
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina adds former Labcorp CEO to board of directors By Investing.com - Investing.com Canada
David P. King elected to Illumina's Board of Directors - PR Newswire
ILMN: All proposals were preliminarily approved, with no questions raised during the Q&A session - TradingView
DNA Methylation Sequencing Market to Reach USD 5.49 Billion - openPR.com
NGS-Based RNA Sequencing Market to Reach USD 15.0 Billion by 2033 - openPR.com
Illumina stock (US4523271090): corporate responsibility push after return to growth - AD HOC NEWS
Illumina stock (US4523271090): Corporate Responsibility Report highlights genomics growth drivers - AD HOC NEWS
Is This the Right Time to Retain ILMN Stock in Your Portfolio? - TradingView
Illumina stock (US4523271090): new responsibility report highlights growth drivers in genomics - AD HOC NEWS
Illumina now sequences over 10 human genomes a minute, trims packaging 87% - Stock Titan
SomaLogic Inc stock (US82489T1043): Illumina takeover reshapes proteomics story - AD HOC NEWS
Illumina stock (US4523271090): analysts see limited upside after volatile Nasdaq recovery - AD HOC NEWS
Illumina price tries to vent off overbought saturationForecast today18-05-2026 - Economies.com
NXP, Illumina, StoneX Group: Momentum Stocks Analysis (Buy & Sell)May 2026News and Statistics - IndexBox
Illumina stock (US4523271090): analysts see limited upside after recent volatility - AD HOC NEWS
Illumina stock (US4523271090): analysts see limited upside after volatile trading - AD HOC NEWS
Illumina Inc stock (US4523271090): spin-off progress and earnings keep investors alert - AD HOC NEWS
Illumina, Inc. Trade Ideas — EUROTLX:4ILMN - TradingView
SomaLogic Inc stock (US82489T1043): Illumina merger closes and reshapes proteomics story - AD HOC NEWS
Illumina Inc stock (US4523271090): gene sequencing player in focus after latest earnings and divesti - AD HOC NEWS
Illumina's new connected multiomics platform set to boost its stock - MSN
Illumina CEO Joins Trump-Xi Summit: Here’s What It Means for ILMN Stock - TIKR.com
Illumina, Inc.Common Stock (Nasdaq:ILMN) Stock Quote - FinancialContent
Illumina's Mid-Teens Clinical Growth Appears Sustainable Over Next 1 to 2 Years, RBC Says - Moomoo
Swiss Life Asset Management Ltd Sells 47,498 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina Insider Sold Shares Worth $47,931,975, According to a Recent SEC Filing - marketscreener.com
Illumina stock (US4523271090): gene sequencing player in focus after leadership and strategy updates - AD HOC NEWS
RBC Capital Mkts resumed coverage on Illumina with a new price target - Quantisnow
Is Illumina (ILMN) Pricing Look Interesting After 77% One Year Share Price Gain - Yahoo Finance
Illumina (ILMN) Coverage Resumed with Outperform Rating and $170 Target - GuruFocus
Illumina director Keith Meister sells $47.9m in shares - Investing.com India
Illumina director Keith Meister sells $47.9m in shares By Investing.com - Investing.com Nigeria
Illumina(ILMN.US) Director Sells US$47.93 Million in Common Stock - Moomoo
Corvex Funds tied to Illumina (NASDAQ: ILMN) sell shares and partly unwind equity swaps - Stock Titan
RBC Capital assumes Illumina stock coverage with outperform rating By Investing.com - Investing.com Australia
RBC Capital assumes Illumina stock coverage with outperform rating - Investing.com
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
[SCHEDULE 13G/A] ILLUMINA, INC. Amended Passive Investment Disclosure - Stock Titan
Illumina stock (US4523271090): Shares up 10.6% YTD amid strong earnings beat - AD HOC NEWS
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):